Menu
Search Close

News

News, Webcasts and interviews

Scancell recruits deal maker to take over as CEO

Executive chairman John Chiplin said new CEO Dr Cliff Holloway's extensive experience and accomplishments speak volumes

Tue, 10 Oct 2017 08:24:00

Scancell on the lookout for partners after year of “significant progress”

“We are continuing to explore a number of funding options to ensure that we have the resources to progress these programmes through their next phase”

Wed, 13 Sep 2017 06:21:00

Scancell presents Moditope data at prestigious cancer conference

Chief scientific officer Lindy Durrant presented two posters at the International Cancer Immunotherapy conference in Germany on Friday

Mon, 11 Sep 2017 09:25:00

Scancell says study reveals Oncimmune technology may assist in its SCIB1 cancer treatment

Scancell has revealed that using Oncimmune's autoantibody technology may help to identify patients who are most likely to respond to its SCIB1 skin cancer treatment in future trials

Tue, 29 Aug 2017 13:35:00

Scancell raises £5mln in 'most successful round they've ever had' - CEO Richard Goodfellow

Richard Goodfellow, chief executive of Scancell Holdings Plc (LON:SCLP) talks through with Proactive Investors their £5mln raise to fund clinical work on their pipeline of cancer immune-therapies.

Fri, 12 May 2017 07:57:00

Scancell boss 'very excited' about collaboration deal with leading US lung cancer foundation

Scancell Holdings Plc (LON:SCLP) has confirmed it will kick off a phase II clinical trial of its potentially breakthrough cancer treatment in the second half.

CEO Richard Goodfellow also tells Proactive's Andrew Scott they've found a partner to help them with a phase I/II clinical study of SCIB2 for patients with lung cancer.

Wed, 01 Feb 2017 09:53:00

Scancell poised for “significant” year with its immuno-oncology portfolio

"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently

Tue, 11 Jul 2017 12:30:00

Scancell’s SCIB1 cancer treatment continues to produce strong survival data

Eight patients have now reached the five year survival milestone, with half of those not seeing any recurrence of the disease during that time

Tue, 11 Jul 2017 05:58:00

Scancell technology receives European patent protection

The ImmunoBody technology was used to develop SCIB1 and SCIB2 – the company’s leading drug candidates.

Mon, 26 Jun 2017 05:47:00

Scancell Holdings raises £5mln as pace of clinical work quickens

The money will support clinical work on its pipeline of cancer immunotherapies and in particular Modi-1, the first product from its Moditope platform.

Thu, 11 May 2017 12:00:00

Scancell rounds up a busy six months

The update was provided as Scancell served up its financial results for the six months ended October 31.

Tue, 31 Jan 2017 08:01:00

Scancell inks collaboration deal with leading US lung cancer foundation

It is teaming up with the Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J Addario Lung Cancer Foundation.

Mon, 30 Jan 2017 07:39:00

Scancell "very optimistic" about US study after "compelling" melanoma trial results

Richard Goodfellow, chief executive officer at Scancell Holdings Plc (LON:SCLP), the developer of novel immunotherapies for the treatment of cancer, talks to Proactive Investors about the “compelling” results from the group's clinical study on a drug for patients suffering from late-stage melanoma.

"These are very powerful data on survival and disease recurrence which are quite unlike, we believe, anything that had previously been seen in other studies," he says.

"We never really expected to be treating patients for so long," he explains. "that is how we discovered patients living up to five years with the disease, which was a surprising finding."

As the group embarks on a clinical trial in the US this year, Goodfellow believes the trial will be successful because "there is tremendous logic to the combination" and says he is "very optimistic" about the study.

Wed, 04 Jan 2017 12:08:00

Scancell hails "compelling" results from clinical trial

The study showed the response to SCIB1 was “significantly stronger” at higher doses, while the drug worked better for those patients who already had the tumour removed before treatment.

Tue, 03 Jan 2017 12:15:00

Scancell boss “very optimistic” about latest drug candidate

Richard Goodfellow, chief executive at drug research firm Scancell Holdings Plc (LON:SCLP), tells Proactive Investors that he has high hopes for the company’s latest drug candidate, SCIB2.

“We’re very optimistic [about SCIB2] and that’s based upon new understanding around how the immune system works, to allow us to manipulate it to improve the prognosis of those patients,” he says.

Goodfellow explains that the lung cancer treatment did “all that we hoped it would in animals” and the company is now preparing SCIB2 for a Phase I clinical trial, which he says has already been designed.

Touching on the company’s lead product, SCIB1, Goodfellow says the skin cancer treatment is showing “remarkable” signs in its latest trials.

He also adds that he was “delighted” after Japanese biologist Yoshinori Ohsumi recently scooped the Nobel Prize for medicine for his work on autophagy, which links in closely with Scancell’s own research.

Mon, 10 Oct 2016 13:30:00

Scancell up 7% after lung cancer announcement

With the aim of heightening its efficacy, SCIB2 will be given with a new breed of cancer treatment called a checkpoint inhibitor.

Mon, 10 Oct 2016 14:05:00

Scancell wants to take more discoveries into the clinic

The board believes that further clinical studies could add significant value to the company and is continuing to explore a number of funding options to ensure that the company has the resources to progress these programmes further - chairman, Dr John Chiplin..

Fri, 16 Sep 2016 05:38:00

Scancell adds heavy hitter to board

Dr Alan Lewis brings "a wealth of industry experience, both commercially and financially," said Scancell chairman Dr John Chiplin

Mon, 22 Aug 2016 06:35:00

Scancell says Ichor deal extension “clears the runway”

Cancer-focused immunotherapy specialist Scancell Holdings Plc (LON:SCLP) has been granted a further extension to its option to license the commercial use of Ichor Medical Systems' proprietary TriGrid electroporation delivery system with SCIB1, Scancell's ImmunoBody vaccine for the treatment of melanoma.

The extension has been granted at no cost to Scancell, chief executive officer Richard Goodfellow told Proactive Investors.

The two technologies work well together to create T-cells that are highly effective in combating cancer.

“Our technology is validating them and their technology is validating us in a way,” Goodfellow said, which may explain why Ichor was keen for Scancell to continue using the system.

“This extension of two years gives us confidence to embark upon the next round of clinical trials that we’re planning in the United States,” Goodfellow declared.

The company is talking on new people in the US and making a bigger splash across the pond, which is engendering a “much broader knowledge of the company within the biotech field”, Goodfellow said.

Wed, 20 Jul 2016 14:31:00

Scancell ever closer to tackling most deadly form of cancer

With cases of skin cancer on the rise, Scancell's immunotherapy study data has come at the right time, but is it enough to offset the insecurity in the sector?

Thu, 21 Jul 2016 09:20:00

Scancell turns to Belgian group to replenish vaccine stocks

Scancell wants the drugs for a US clinical study of SCIB1 in combination with a checkpoint inhibitor

Thu, 21 Jul 2016 06:38:00

Scancell extends commercial licence with Ichor

Scancell will continue to use Ichor’s electroporation delivery system in conjunction with its flagship skin cancer vaccine.

Wed, 20 Jul 2016 05:19:00

Scancell’s cancer vaccine programme boosted by scientific review

“We believe this platform has the potential to develop a new class of immuno-oncology therapeutics and look forward to progressing our first vaccine into the clinic as soon as possible."

Wed, 13 Jul 2016 05:25:00

Scancell Holdings says SCIB1 survival data is compelling

Chief executive Dr Richard Goodfellow told investors that the drug continues to deliver compelling survival data in patients

Wed, 06 Jul 2016 07:31:00

Scancell's SCIB1 offers patient opportunities - Panmure's Mitchell

Dr Mike Mitchell, healthcare analyst at Panmure Gordon, remains excited about Scancell Holdings Plc’s (LON:SCLP) flagship cancer drug SCIB1 in spite of the company withdrawing the current batch. 

He says Scancell did so as some of the material had been stored for over seven years and fallen out of the original specification. “

Effectively what you’ve got is a dose that perhaps doesn’t have as much of the expected dose of the active agent as would be anticipated.”

Mitchell highlights the “very good side effect profile,” of the cancer drug adding “SCIB1 in particular and the wider platform for Scancell holds some very interesting opportunities and potential for cancer patients in otherwise very difficult to treat indications.”

Fri, 17 Jun 2016 11:13:00

Scancell working quickly to secure new supplies of drug

The company said that quality control analysis revealed the “stored drug product is no longer within the original specification”.

Fri, 17 Jun 2016 13:27:00

Scancell's immunotherapy platform to fight brain cancer

Glioblastoma multiforme is one of the most common and most aggressive forms of brain cancer.

Thu, 02 Jun 2016 06:42:00

Combined immunotherapies provide hope for skin cancer cure

Cancer researchers have combined two immunotherapies to completely eradicate cancer.

Wed, 01 Jun 2016 07:54:00

Scancell undergoes management reshuffle

Scancell pursues a management reshuffle to support growth plans outlined in its latest fundraiser.

Wed, 18 May 2016 06:13:00

Scancell Holdings PLC brings in £6.2mln in fundraise

Scancell Holdings PLC revealed it had raised a total of around £6.2mln from its open offer and share placing. n.

Mon, 04 Apr 2016 08:59:00

Webcasts, Interviews and Media Coverage

Scancell recruits deal maker to take over as CEO

Executive chairman John Chiplin said new CEO Dr Cliff Holloway's extensive experience and accomplishments speak volumes

Tue, 10 Oct 2017 08:24:00

Scancell on the lookout for partners after year of “significant progress”

“We are continuing to explore a number of funding options to ensure that we have the resources to progress these programmes through their next phase”

Wed, 13 Sep 2017 06:21:00

Scancell presents Moditope data at prestigious cancer conference

Chief scientific officer Lindy Durrant presented two posters at the International Cancer Immunotherapy conference in Germany on Friday

Mon, 11 Sep 2017 09:25:00